Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 25, 2014 - Issue 4
Submit an article Journal homepage
574
Views
43
CrossRef citations to date
0
Altmetric
Non-laser cosmetic approaches

Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A

Jae Hyung LeeDepartment of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Ji Ho ParkDepartment of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Soo Keun LeeKorean Society of AntiAging Dermatology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Kwang Ho HanKorean Society of AntiAging Dermatology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Sang Duck KimKorean Society of AntiAging Dermatology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Chun Sik YoonKorean Society of AntiAging Dermatology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Jae Young ParkKorean Society of AntiAging Dermatology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Joo Heung LeeDepartment of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
,
Jun Mo YangDepartment of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
&
Jong Hee LeeDepartment of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaCorrespondence[email protected]
 show all
Pages 326-330 | Received 09 Oct 2012, Accepted 11 Jan 2013, Published online: 02 Jun 2013

References

  • Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26:e1–e9.
  • Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H. Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins–a single cohort 4-year follow-up study. BMJ Open. 2012;2.
  • Sattler G, Callander MJ, Grablowitz D, Walker T, Bee EK, Rzany B, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;36:2146–2154.
  • Imhof M, Kuhne U. A phase III study of IncobotulinumtoxinA in the treatment of glabellar frown lines. J Clin Aesthetic Dermatol. 2011;4:28–34.
  • Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–1049.
  • Carruthers JD. Ophthalmologic use of botulinum A exotoxin. Can J Ophthalmol. 1985;20:135–141.
  • Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743–1746.
  • Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006;9:145–148.
  • Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996;46:26–29.
  • Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm. 2004;61:S5–S10.
  • Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186–1188.
  • Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13:10–19.
  • Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther. 2008;10:181–183.
  • Dressler D. Five-year experience with incobotulinumtoxinA(Xeomin®): the first botulinum toxin drug free of complexing proteins. Eur J Neurol. 2012;19:385–389.
  • Tang-Liu DD, Aoki KR, Dolly JO, de Paiva A, Houchen TL, Chasseaud LF, et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon. 2003;42:461–469.
  • Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57:555–565.
  • Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64:1949–1951.
  • Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–312.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.